Skip to main content

DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare

Written by Customer Service on . Posted in Public Companies.

BROSSARD, Quebec, Dec. 16, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to announce the appointment of Dr. Ismail Ben Ayed, as Chief Artificial Intelligence (AI) Scientist.

Mr. Ben Ayed is an expert in medical image analysis algorithms, machine learning and computer vision. Mr. Ben Ayed will guide the Company’s strategic direction in AI research and development. His mandate includes advancing the accuracy, efficiency, and clinical utility of DIAGNOS’ proprietary CARA (Computer-Assisted Retinal Analysis) System platform and expanding AI capabilities to support detection of eye related diseases.

A recognized leader in AI for Medical Imaging

Dr. Ben Ayed is a full-time Professor at the Department of System Engineering at École de Technologie Supérieure (ÉTS) in Montreal and co-director of the LIVIA (Laboratoire d’Imagerie, Vision et Intelligence Artificielle) research center. Before joining the ETS in 2015, he worked as a research scientist at GE Healthcare. He has an extensive publication record including over 150 peer-reviewed articles.

“We are thrilled to welcome Ismail to our leadership team,” said André Larente, president of DIAGNOS. “His experience in deep learning and medical imaging aligns perfectly with our mission to leverage AI to improve patient outcomes globally.

Future vision for DIAGNOS

In his role, Mr. Ben Ayed will focus on:

  • Driving the development of the next-generation Visual AI tools powering CARA System and future DIAGNOS innovations
  • Advising and expanding the Company’s in-house AI and Scientific team
  • Establishing and strengthening academic and industry partnerships to accelerate development and validation of clinical AI solutions

“I have long followed DIAGNOS’ commitment to making cutting-edge AI accessible for the early detection of retinal diseases,” said Dr. Ben Ayed. My focus will be on accelerating the development of robust, generalizable, and clinically validated AI models that can scale globally and truly transform preventative care.”

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.

Additional information is available at www.diagnos.com and www.sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.